FY2026 EPS Estimate for Olema Pharmaceuticals Cut by Analyst

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 12th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($2.25) per share for the year, down from their previous forecast of ($2.23). HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ FY2027 earnings at ($2.32) EPS, FY2028 earnings at ($1.98) EPS, FY2029 earnings at ($1.56) EPS and FY2030 earnings at ($0.83) EPS.

Other research analysts have also recently issued research reports about the stock. Citigroup raised their price target on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Guggenheim lowered their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday. Wall Street Zen raised Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. Stifel Nicolaus began coverage on Olema Pharmaceuticals in a research report on Wednesday, February 11th. They set a “buy” rating and a $48.00 target price for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.10.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $13.58 on Thursday. The stock has a market cap of $1.19 billion, a P/E ratio of -6.72 and a beta of 2.05. The company’s 50-day simple moving average is $15.79 and its 200 day simple moving average is $20.45. Olema Pharmaceuticals has a twelve month low of $3.89 and a twelve month high of $36.26. The company has a quick ratio of 9.95, a current ratio of 9.95 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52).

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares during the last quarter. Torren Management LLC bought a new stake in Olema Pharmaceuticals during the 4th quarter worth approximately $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Olema Pharmaceuticals during the 4th quarter valued at $88,000. Nisa Investment Advisors LLC increased its holdings in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Olema Pharmaceuticals by 44.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after purchasing an additional 1,169 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, insider Shawnte Mitchell sold 25,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.56% of the stock is owned by corporate insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.